Porocarcinoma chemotherapy

Chemotherapy For Cancer: How It Works, What It Is, What To Expect, Side Effects, Benefits. Chemotherapy Is a Type Of Cancer Treatment That Uses Drugs To Kill Fast Cancer Cell Complete response of a metastatic porocarcinoma treated with paclitaxel, cetuximab and radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use Cetuximab / administration & dosage Chemoradiotherapy, Adjuvant / methods*. Metastatic eccrine porocarcinoma successfully treated with carboplatin and epirubicin chemotherapy. J Dermatol. 2015 Sep;42 (9):928-30. doi: 10.1111/1346-8138.12977. Epub 2015 Jun 13 While many treatment modalities, including electrocautery, electrofulgaration, radiation therapy, locoregional chemotherapy, and isotretinoin (1-3 mg/kg/day for up to 10 months often in combination with other chemotherapy), have been used for primary porocarcinoma, most authors agree that complete excision with clear margins is necessary in controlling the progression of disease

Porocarcinoma is a rare sort of skin cancer developing from sweat glands, specifically, it is a malignancy of the eccrine sweat glands. Its etiology is not well understood. However, some studies have showed that the tumor developed from a pre-existing eccrine poroma Metastatic disease developed nine months following primary surgical treatment. The metastatic eccrine porocarcinoma was resistant to epirubicin but responded to docetaxel chemotherapy. Conclusions There are no data to support the use of adjuvant therapy in the management of eccrine porocarcinoma

Chemotherapy Benefits - Chemotherapy For Cance

Complete response of a metastatic porocarcinoma treated

Eccrine porocarcinoma (EPC) is a rare skin malignancy that represents around 0.01% of all skin tumors.1,2 There is a wide range of clinical presentations of this neoplasm such as papules, plaques, and nodules. Most tumors appear in the head and neck region or on the lower extremities, but all body parts can be involved. EPC is frequently clinically misdiagnosed as squamous cell carcinoma or. Eccrine porocarcinoma can be aggressive and is known to metastasise or spread to other organs of the body, causing death. The tumour cells commonly disseminate via the lymphatic vessels. Hence the physician should examine the regional lymph nodes. Primary treatment consists of excising the tumour

The treatment of Porocarcinoma of Skin may involve the following: In most cases, a wide surgical excision and removal of the entire tumor is the preferred treatment option. This may be followed by radiation therapy and/or chemotherapy Porocarcinoma is a very rare entity and poorly understood. In the metastatic phase, it has modest or no sensitivity to anticancer treatment. Docetaxel should be considered in the metastatic eccrine porocarcinoma. 1 Eccrine porocarcinoma (EPC) is an exceedingly rare cutaneous adnexal tumor with high potential for morbidity and mortality. (Nazemi et al., 2018) Although any body site can be affected, EPC typically presents on the head and neck Eccrine porocarcinoma (EPC) is a rare type of skin cancer arising from the intraepidermal portion of eccrine sweat glands or acrosyringium, being a primary tumor or, even more common, a malignant transformation of an eccrine poroma (EP), representing 0.005-0.01% of all cutaneous tumors [ 1 ]. In Europe, the incidence rate was < .28/100,000 [ 2 ]

Eccrine porocarcinoma is an extremely rare skin adnexal malignant neoplasia with highly invasive and metastatic potential. We report an additional case of eccrine porocarcinoma with intracranial metastases. This case is characterized by a complete record of the progress of eccrine porocarcinoma, its immunohistochemistry after three operations showed a progressive increase in the level of Ki-67. Eccrine porocarcinoma is a rare malignant adnexal tumor arising from the intra dermal part of the sweat gland accounting for 0.005% of all epithelial cutaneous tumors. It is the malignant counterpart of common benign adnexal tumor (eccrine poroma) and is also termed as malignant hidroacanthoma simplex, eccrine poroepithelioma, malignant.

Metastatic eccrine porocarcinoma successfully treated with

  1. Based on the literature, the role of chemotherapy in the treatment of EPC remains unclear. Orphan cases with good responses to 5-fluorouracil [ 14 ], thiotepa and Cytoxan (cyclophosphamide) [ 15] have been reported. However, other studies have described cases showing no clinical response to chemotherapy [ 16 ]
  2. Chemotherapy has been very infrequently employed [3, 5-7]. Metastatic eccrine porocarcinoma has proven to be very resistant to many chemotherapeutic agents. The use of docetaxel in the management of this severe disease with therapeutical success was previously documented
  3. Although porocarcinoma is perceived as a chemo-resistant disease, there have been reports of successful treatment of metastatic disease with specific regimens including carboplatin and epirubicin [6], and paclitaxel and cetuximab [7] After obtaining fully informed, voluntary consent

Porocarcinoma is a rare carcinoma, little known and madly aggressive, with a high recurrence rate and metastatic involvement. The mainstay of treatment is surgical resection in resectable patients and, for those with metastatic involvement, chemotherapy, and radiotherapy are the therapeutic options porocarcinoma is not known.[5] The most frequent tumor localization is in the lower extremities, abdomen, or scalp. [6] The basic treatment of eccrine porocarcinoma is surgi-cal removal of the tumor.[7, 8] The benefits of chemotherapy and radiotherapy are ambiguous.[6] Case Report A 49-year-old male patient presented with the complaint o

Malignant tumors arising from the vulva account for only 0.6 % of all cancers in female patients. The predominant histologic type, representing about 90 % of these malignancies, is squamous cell carcinoma. Eccrine porocarcinoma is a rare malignant tumor arising from sweat glands. The incidence of eccrine porocarcinoma is estimated at 0.005-0.01 % of all cutaneous tumors Eccrine porocarcinoma is a rare malignant sweat gland tu-mor arising from the intraepithelial ductal parts of the sweat gland that was first reported in the literature by Pinkus and Mehregan in 1963 [1]. Initially coined as an epidermotrophic eccrine porocarcinoma, this rare type of malignant tumor wa Introduction. Eccrine porocarcinoma (EPC) is a rare malignant cutaneous tumor with high rates of extracutaneous spread. It has first been described by Pinkus and Mehregan in 1963 [].EPC accounts for 0.005-0.01% of all malignant cutaneous tumors and arises from eccrine sweat gland tumors [].Due to its uncommon onset, EPC can be misdiagnosed as other skin neoplasms, and optimal management is. Eccrine porocarcinoma is a rare malignant cutaneous tumor with high rates of extracutaneous spread, and its diagnosis and management can be quite challenging. This is a case of an 82-year-old woman presenting with an asymptomatic and chronic pubic skin lesion for whom the work-up required many investigations and procedures to confirm the. Approach Considerations. The literature on treatment of eccrine carcinomas is very sparse. While surgery remains the treatment of choice, some cases of distant metastases have been treated with radiation therapy. [ 5] In one radiotherapy-resistant case of eccrine carcinoma, brachytherapy was used. [ 23

Eccrine poroma was first described in 1956. 1 It is a rare benign adnexal tumour which arises from sweat glands of eccrine origin. It tends to present as a non-pigmented lesion, typically found on acral sites such as the soles and palms. It is more prevalent in the 40-60 years old age group, with no gender preference Stay in the Comfort of Your Home For After Chemo Care. Ask Your Doctor Today A case of metastatic eccrine porocarcinoma without actionable mutations treated with carboplatin and epirubicin chemotherapy Fukuda K, Funakoshi T, Fukuyama M, Kakuta R, Sato M, Nakamura Y et al. Metastatic eccrine porocarcinoma successfully treated with carboplatin and epirubicin chemotherapy. Journal of Dermatology . 2015 Sep 1;42(9):928-930 The benefits of chemotherapy in the treatment of metastatic eccrine porocarcinoma are generally poor. Several chemotherapeutic agents, including docetaxel (13), have shown a partial response. In our case, the patient was treated with 6 cycles of chemotherapy with cyclophosphamide, cisplatin and doxorubicin, but with an unsatisfactory response

positive nodes, adjuvant chemotherapy and radiotherapy were administered following which patient showed complete response but subsequently the patient had regional nodal recurrence for which he was irradiated. Conclusion Eccrine porocarcinoma is a rare malignant adnexal tumor of skin which is diagnosed based on the morphological characteristics EPC is a rare malignancy of the eccrine sweat glands that most commonly presents in the sixth to seventh decade in men and women equally. 1 It may arise as a primary sweat gland tumor or result from malignant transformation of an eccrine poroma, a benign sweat gland tumor. 2 Since it was first described by Pinkus et al 3 in 1963, fewer than 300 cases have been reported. 4 Given that eccrine.

Plunkett TA, Hanby AM, Miles DW, Rubens RD (2001) Metastatic eccrine porocarcinoma: Response to docetaxel (Taxotere) chemotherapy. ESMO 12: 411-414. Aaribi I, Mohtaram A, Ameur El-Youbi MB, Kharmoum J, El-Kabous M, et al. (2013) Successful management of metastatic eccrine porocarcinoma Eccrine porocarcinoma (EP) is a rare malignant skin neoplasm, accounting for approximately 0.005%-0.01% of all malignant skin tumors. 1 It is a malignant counterpart of poroma and was first described in 1967, 2 and only 453 cases were reported until 2017. 3 It is often seen in the lower extremities of elderly patients aged >60 years. 3,4 Because of its scarcity, the natural course and.

Eccrine porocarcinoma is a rare malignant tumor that develops in the eccrine glands, appearing as a primary tumor, or by malignant transformation of an eccrine poroma. It is a carcinoma with high metastatic and recurrent potential; it has the same incidence in both sexes, and mainly affects the elderly. Its diagnosis, rather than clinical, is histological, and due to the rarity of the disease. The cause of Porocarcinoma of Skin is unknown, but it could be influenced by the presence of another skin condition called nevus sebaceus; The treatment of choice is a surgical excision with clear margins followed by radiation therapy or chemotherapy, as decided by the healthcare provide Sir: Eccrine porocarcinoma is a rare cutaneous adnexal malignancy. 1 Its variable presentation makes it difficult to diagnose. As a result, the diagnosis and appropriate treatment is often delayed, thereby providing time for the cancer to spread throughout the body, with lethal consequences. 1 Treatment has traditionally consisted of surgical excision with wide margins; however, because of its. Click on the article title to read more

The patient received five cycles of chemotherapy, but later developed renal failure and eventually chose palliative care. CONCLUSIONS: A rash-like presentation of skin metastasis to the trunk and metastasis to the ear from a primary eccrine porocarcinoma is rare. Early diagnosis and adequate surgical resection are recommended to reduce patient. Eccrine porocarcinoma is a rare malignancy of the eccrine sweat gland. It is usually found frequently on the lower extremities, and it affects both sexes equally usually in the sixth to seventh decade. In our case, we present a 42-year-old male patient with a recurring exophytic tumor on the right lower extremity without local extension. The initial tumor was biopsied, excised and diagnosed as. To our knowledge, this is the first report of porocarcinoma studied with MRI imaging. The surgical procedure obtained complete resection of the neoplasm. The patient, without undergoing chemotherapy, had a good reprise of her normal life appearing free of disease at 15 months from the surgical procedure

Porocarcinoma (Malignant Poroma, Eccrine Porocarcinoma

Eccrine porocarcinoma is a rare cancer and so can sometimes be difficult to diagnose. Diagnosis is usually made with a skin biopsy of the affected area where a small sample of tissue is taken so that it can be examined under a microscope. body, treatments such as radiotherapy and chemotherapy may be considered. Self care (What can I do? Although porocarcinoma is perceived as a chemo-resistant disease, there have been reports of successful treatment of metastatic disease with specific regimens including carboplatin and epirubicin , and paclitaxel and cetuximab After obtaining fully informed, voluntary consent, we describe a case of the successful treatment of locally recurrent. Neither chemotherapy nor radiotherapy was of much clinical benefit to patient. Our patient presented lately with multiple metastases and chemotherapy is not of much use. So any patient post radiotherapy was monitored regularly for radiation induced tumours. If porocarcinoma is diagnosed then wide surgical excision is planned without any delay porocarcinoma (EPC), primarily localized in the breast, was referred to our hospital. Two years earlier she under went a lumpectomy for a Because of limited evidence for chemotherapy in a patient already compromised by advanced age and multi-comorbidity (including diabetes, thrombo-embolic events and obesity) it was decided to withhold. Treatment of porocarcinoma is primary excision and sentinel lymph node biopsy . Because it has metastatic potential, chemotherapy has been tried, but consistent results are not reported [5, 6]. It may arise in continuity with a benign preexistent poroma . We report an example of malignant eccrine poroma arising in a preexisting poroma after the.

(Background) Porocarcinoma is a rare eccrine sweat gland tumor, and a valied treatment is not yet determined for metastatic disease because of the chemo-resistant and radio-resistant nature of this tumor. (Case) This report describes a case of porocarcinoma arising on the penile shaft of 83-year-old man with extensive lymph node metastases 03/01/2001 - The metastatic eccrine porocarcinoma was resistant to epirubicin but responded to docetaxel chemotherapy. 04/01/1997 - A new chemotherapy protocol consisting of isotretinoin and interferon alpha has confirmed the advantages of polychemotherapy in the treatment of metastatic malignant eccrine poroma Drug Therapy (Chemotherapy) 9/2015: Metastatic eccrine porocarcinoma successfully treated with carboplatin and epirubicin chemotherapy. Join CureHunter, for free Research Interface BASIC access! Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease Interestingly, there is no established medical protocol for the treatment of porocarcinoma. Radiotherapy, chemotherapy and acitretin have been used against this cancer with varying degrees of success. A new drug that I am receiving, Keytruda (Pembrolizumab), inhibits the growth and spread of cancer cells and accelerates white blood cells that.

Porocarcinoma; presentation and management, a meta

  1. Treatment modalities for porocarcinoma have included Mohs micrographic surgery, standard surgical excision with broad tumor margins, radiation therapy, and chemotherapy. The Mohs micrographic surgery affords, for some authors, the greatest likelihood of cure in the absence of regional and distant metastases and clear margins
  2. Eccrine poromatosis has been reported in patients with lymphoproliferative disorders that have been treated with chemotherapy. Onset has varied from during the chemotherapy until years after. Rarely, malignant eccrine poroma, or porocarcinoma, develops, either de novo or by transformation within a benign eccrine poroma
  3. BACKGROUND:Eccrine porocarcinoma, or malignant eccrine poroma, is a rare primary skin tumor that develops in the sixth and seventh decades of life, and can present as a painless and solitary nodule. Histopathology is required to confirm the diagnosis. A rare case is presented of metastatic eccrine porocarcinoma, occurring four years after surgical excision of the primary scalp tumor, and.
  4. A biopsy confirmed metastatic subungal eccrine porocarcinoma. He started receiving palliative chemotherapy with carboplatin and paclitaxel [routes and dosages not stated]. After four chemotherapy cycles, excellent clinical and radiographic response was noted
  5. The nose is a relatively common spot for skin cancer to develop. Skin cancer often starts on the face because it's usually the body part that's exposed to the sun.   The two most common types of skin cancer that develop on the nose are basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). While both types of skin cancer should be addressed right away, BCC is usually slow.

Metastatic eccrine porocarcinoma: Response to docetaxel

  1. Eccrine porocarcinoma is a rare type of skin cancer involving a type of sweat gland called the eccrine glands. Eccrine sweat glands are present in the skin, with the highest density on the palms, soles, face and scalp. Eccrine porocarcinoma is typically a slow-growing tumour which is more common in those who are over 60 years of age, and occurs.
  2. Cite this article as. Ponzetti A, Ribero S, Caliendo V, Spadi R, Macripò G, Lista P. Long-term survival after multidisciplinary management of a metastatic sarcomatoid porocarcinoma with repeated exeresis, radiotherapy, chemotherapy and cetuximab: case report and review of literature
  3. istered to.
  4. Combination of Docetaxel and Gemcitabine Ineffective in Metastatic Eccrine Porocarcinoma A Case Report-Hilmi Kodaz. Download PDF. Download Full PDF Package. This paper. A short summary of this paper. 37 Full PDFs related to this paper. READ PAPER

Response to taxane-based chemotherapy in metastatic

I started radiation immediately, followed by chemotherapy. It did the trick. My doctor said I would die before Christmas. Two years later, I'm living and thriving with cancer again Electrochemotherapy. Authoritative facts from DermNet New Zealand. What drugs are used with electrochemotherapy? Bleomycin is the chemotherapy drug most commonly used for electrochemotherapy. Cisplatin can be used if bleomycin is unsuitable, for example, if the maximum safe dose of bleomycin has been exceeded or if there have been unacceptable side effects from bleomycin Sweat gland carcinomas are regarded as resistant to radiotherapy. Chemotherapy has been very infrequently employed [3, 5-7]. Metastatic eccrine porocarcinoma has proven to be very resistant to many chemotherapeutic agents. The use of docetaxel in the management of this severe disease with therapeutical success was previously documented In mid April, 2012 I was diagnosed with sweat gland cancer, in my right upper leg (adnexal carcinoma with eccrine feature, etc). I was told that this was also a very rare and slow growing tumor. I wasn't sure what to think, but have done a lot of research since then. In mid May was the bulk of the tumor removed Porocarcinoma is a rare skin appendage carcinoma, with a poor prognosis. At present, the recommended treatment of localized porocarcinoma is wide surgical resection. Although anthracyclin‑based chemotherapy or combination of 5‑fluorouracil (5-FU), taxanes and cisplatin are considered to be the first‑line treatment for metastatic or locally‑advanced porocarcinoma, this type of tumor is.

Eccrine porocarcinoma: A rare case of an in situ tumor

Chemotherapy is an adjunct in the setting of bulky or unresectable disease. Related Articles. Severe Lichenoid Drug Eruption from Pembrolizumab. HISTORY An 88-year-old woman with a six-month history of a diffuse, pruritic eruption that includes thick, hypertrophic leg lesions with accompanying edema, ulcerations, weeping exudates and pain. Metastatic eccrine porocarcinoma: response to docetaxel (Taxotere) chemotherapy. Ann Oncol 2001;12:411-14. 14.Dummer R, Becker JC, Boser B et al. Successful therapy of metastatic eccrine poroma using perilesional interferon-alpha and interleukin-2

Eccrine Porocarcinoma: A Multicenter Retrospective Study

OBJECTIVE: To call attention to a new therapeutic protocol in the treatment of metastatic porocarcinoma, as well as to underline an antineoplastic efficacy of vitamin A analogues. METHODS: The results are presented on the basis of the clinical case of a malignant eccrine poroma with metastatic regional lymph nodes That treatment is intralesional chemotherapy. It is a rarely employed and actually works. Although 5-fluorouracil is the most common intralesional chemotherapeutic option for BCC and SCC, many other agents have been shown to be as effective. They include bleomycin and various interferon subgroups A telephone triage service for patients wanting to come to see a consultant specialist at Spire. A dedicated phone line staffed by nurses. If you are currently having treatment at Spire Leeds Hospital and would like to talk to one of our specialist chemotherapy nurses call 0113 218 5950 or 0113 218 5658

Adnexal Squamous Cell Carcinoma Recurring in Parotid

Pathophysiology. There is damage to sweat glands and suppression of sweating, which disrupts thermoregulation. Eccrine carcinoma may be derived de novo from any portion of the normal eccrine apparatus or result from the transformation of an existing benign eccrine tumor. A 2000 study by Takata et al [ 2] examining the incidence of cytogenetic. Eccrine carcinoma is a rare skin condition characterized by a plaque or nodule on the scalp, trunk, or extremities.: 669 It originates from the eccrine sweat glands of the skin, accounting for less than 0.01% of diagnosed cutaneous malignancies. Eccrine carcinoma tumors are locally aggressive with a high rate of recurrence. Lack of reliable immunohistochemical markers and similarity to other.

Metastatic Hidradenocarcinoma: Efficacy of CapecitabinePPT - Andrew’s Diseases of the Skin Epidermal Nevi

Eccrine porocarcinoma DermNet N

Malignancy is a well-recognised complication of transplantation and can occur de novo, as a recurrence of a pre-existing malignancy, or from transmission of malignancy from the donor. Common de-novo malignancies are those of the skin and the lymphoreticular system. Various solid-organ cancers have also been reported in transplant recipients and each poses a unique management challenge in view. AbstractEccrine porocarcinoma is a rare type of skin cáncer arising from the intraepidermal portion of eccrine sweat glands, representing no more tan 0.01% of all cutaneous tumors. 20% of the Eccrine porocarcinoma will recur and 20% will metastasize to regional lymph nodes. Few cases of distant metastases has been reported Code Preferred Term Synonyms Definition Neoplastic Status C7419 Acanthoma A benign skin neoplasm composed of epithelial cells. Benign C3173 Accelerated Phase Chronic Myelogenous chemotherapy, he was planned for palliative radiotherapy 30 Gy in 10 fractions completed over a period of 2 weeks. He responded well with almost 60% clinical response. ABSTRACT Eccrine Porocarcinoma (ECP) is a malignant tumour arising from the intraepithelial ductal parts of the sweat gland. It ha

Abbas AGAIMY | Professor of Pathology and Vice Chair

Porocarcinoma of Skin - DoveMe

Ponzetti A, Ribero S, Caliendo V, Spadi R, Macripò G, Lista P. Long-term survival after multidisciplinary management of a metastatic sarcomatoid porocarcinoma with repeated exercises, radiotherapy, chemotherapy and cetuximab: Case report and review of literature. G Ital Dermatol Venereol 2017;152:66-70 Eccrine Porocarcinoma is a rare, slow growing malignant tumor of eccrine sweat gland. The most common site of this tumor is lower extremity. It is characterized histologically by anaplastic cells with eccrine ductal structures which may be adjacent to a benign eccrine poroma. We present here a case of Eccrine Porocarcinoma in lower extremity. Introduction. Eccrine porocarcinoma (EP) was described in 1963 by Pinkus and Mehregan, 1 but it was Mishima and Morioka 2 who introduced this name in 1967. EP is a rare neoplasm (0.005% to 0.01% of all malignant skin tumors). 3 It arises most commonly on the lower limbs 4-6 and on the head and neck 7-9 of patients of advanced age, 10 with no difference between the sexes. 5,7 Clinical.

Successful Management of Metastatic Eccrine Porocarcinom

Eccrine porocarcinoma (EP), a particular malignant sweat gland tumor, represents only 0.005% of epithelial cutaneous neoplasms. The first reported case was attributed A single patient received palliative chemotherapy after unresectable local recurrence, while another two patients underwent adjuvant radiation therapy, one for clos Eccrine porocarcinoma (EPC), also known as malignant eccrine poroma, is a relatively common form of sweat gland carcinoma, arising from the intraepithelial ductal portion ofthe gland. The tumor most often occurs in the elderly, with men affected more than women. Approxi­ mately 50% of the tumors occur on the lower extremities Radiation therapy has been used in select cases while chemotherapy has not been used extensively. This cancer has a tendency to recur and can also spread (metastasize) to other parts of the body. I was able to find a clinical case study from 2013. The study authors noted that if treated early, eccrine porocarcinoma can be curable through surgery

Occurrence of metastatic eccrine porocarcinoma in an

Eccrine porocarcinoma (EPC) is a rare malignant cutaneous adnexal tumor 1, 2.The reported frequency of EPC is 0.005% to 0.01% of all cutaneous tumors, making it the most common malignant eccrine tumor 3.Since EPC is notoriously known for being mis- or overdiagnosed, its actual prevalence remains unknown 1.It can arise de novo or from long-standing pre-existing eccrine poroma (EP) 2, 4 chemotherapy. At the age of 62 years, the patient presented with a subcutaneous nodule around the surgical scar on the right lower abdomen, measuring 20 mm in diameter (Fig. 1A). One year after we performed an excisional biop- Eccrine porocarcinoma 2 10/23 (43.5) 10/24 (41.7) Topics: Adjuvant, Antineoplastic Combined Chemotherapy Protocols, Chemoradiotherapy, Eccrine Porocarcinoma, Humans, Cetuximab, Female, Local, Middle Aged, Neoplasm. On June 21st 2013,My 31 year old husband was recently diagnosed with a very rare, most aggressive form of cancer..Malignant Eccrine Porocarcinoma. Apparently it started in his sweat glands. There have been less than 300 cases ever reported in the world and unfortunately they don't know a lot about it

Welcome. Welcome to Arkansas Cancer Institute. In the treatment of cancer, our expert medical oncologists and skilled radiation oncologist, along with an experienced and dedicated staff, provide constant support and assistance, treating each patient and family with the kindness and respect they deserve ao Won JH, Je-Ho M, Kim BJ 21 To Cases of Scalp ccrine Porocarcinoma ith Revie of iterature. J Clin Case Rep : 12. Page 3 of 3 oe e • 2 ae e a oe ae oa 22 presented multiple poor histopathologic features. Infiltrative tumor margins, a mitotic count of 16/HPF, and a tumor depth >10 mm wit Histopathology confirmed the presumptive clinical diagnosis of cutaneous metastasis of eccrine porocarcinoma. Abundant cellular atypia was observed, as were desmoplastic stroma and large tumor nests composed of epidermal cells that invaded the papillary and reticular dermis and, focally, the hypodermis, leaving areas of central necrosis and forming ducts with eccrine differentiation (Fig. 2A) Malignant eccrine poroma, also known as eccrine porocarcinoma (EPC), is a tumor arising from the epidermal portion of eccrine sweat gland. This tumor may occur de novo or develop from a preexisting lesion as degenerative progression, and it can manifest clinically as a solitary lesion with ulceration or as a plaque, polypoid, or verrucous lesion. It mostly affects the elderly, and most. Snow SN, Reizner GT (1992) Eccrine porocarcinoma of the face. J Am Acad Dermatol 27:306-311 include high mitotic index, lymphovascular invasion, tumor 9. van Gorp J, van der Putte S (1993) Periungal eccrine porocarcinoma. depth (in this case, greater than 7 mm), and infiltrative tumor Dermatology 187:67-70 margins [3]. 10 Although MCC shows a relatively high RR to first-line chemotherapy, the response is rarely durable, and resistance develops quickly. One retrospective study has reported RRs of 69 and 57% to first-line chemotherapy for locally advanced and metastatic MCC, respectively, but survival was limited to averages of 24 and 9 months, respectively